Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 28, 2020	Mar. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers among level 1, 2, and 3	$ 0.0			$ 0.0
Income recognized from change is asset	1.6	$ 10.4
Royalty Pharma Contingent Milestone Payments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net sales included in calculation for milestone payment				0.0	$ 337.5
Payments received		250.0
Royalty Pharma Contingent Milestone Payments | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment		10.4
Estimated fair valued contingent milestone payment	96.9	83.6		$ 95.3	$ 323.2
Payments received	0.0	$ 250.0
Royalty Pharma 2020 Contingent Milestone Payments | Measured on a recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of milestone payment	1.6
Estimated fair valued contingent milestone payment	$ 96.9
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility	35.00%	30.00%
Rate of return	7.29%	8.02%
Scenario, Forecast
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty Pharma contingent payment sales threshold			$ 400.0
Scenario, Forecast | Royalty Pharma Contingent Milestone Payments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty Pharma contingent payment sales threshold			400.0
Net sales threshold to trigger milestone payment			351.0
Income recognized from change is asset			$ 303.1